Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.2200 +0.0200 (+10.00%)

Official Closing Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 8 Next >

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial ↗

June 29, 2022

Via Benzinga

Can Fite Biofarma: Q1 Earnings Insights ↗

May 26, 2022

Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement.

Via Benzinga

Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗

July 12, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗

July 12, 2022

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.

Via Benzinga

Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

July 11, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗

July 01, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...

Via Benzinga

Aspen Aerogels And 28 Stocks Moving Premarket ↗

June 30, 2022

Gainers

Via Benzinga

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗

June 30, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...

Via Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data ↗

June 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

June 29, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

June 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

June 09, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2 ↗

May 26, 2022

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1...

Via Benzinga

Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

May 26, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Granted Key NASH Patent in Israel

May 16, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

May 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis? ↗

April 12, 2022

Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug

April 05, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

March 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update ↗

March 24, 2022

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced

Via Benzinga

This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants ↗

March 24, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

March 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

March 14, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX ↗

March 11, 2022

Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)...

Via Benzinga

Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study ↗

March 08, 2022

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson...

Via Benzinga

Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor? ↗

February 03, 2022

Photo by Diana Polekhina on Unsplash

Via Benzinga

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

January 31, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.